1. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394
2. Григорьева Н.Ю., Кузнецов А.Н., Шарабрин Е.Г. Место хронической обструктивной болезни легких в развитии сердечнососудистого континуума. Сердце: журнал для практикующих врачей. 2012;11(2):120–2
3. Choudhury G, Rabinovich R, MacNee W. Comorbidities and Systemic Effects of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine. 2014;35(1):101–30. DOI: 10.1016/j.ccm.2013.10.007
4. Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global Initiative for Chronic Obstructive Lung Disease: The Changes Made. Cureus. 2019;11(6):e4985. DOI: 10.7759/cureus.4985
5. Marçôa R, Rodrigues DM, Dias M, Ladeira I, Vaz AP, Lima R et al. Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2018;15(1):21–6. DOI: 10.1080/15412555.2017.1394285
6. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer SPM et al. Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). The American Journal of Cardiology. 2014;114(10):1497–503. DOI: 10.1016/j.amjcard.2014.08.013
7. Mohr FW, Morice M-C, Kappetein AP, Feldman TE, Ståhle E, Colombo A et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. The Lancet. 2013;381(9867):629–38. DOI: 10.1016/S0140-6736(13)60141-5
8. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE et al. Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis. JAMA. 2008;300(2):197–208. DOI: 10.1001/jama.300.2.197
9. Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 2016;67(23):2719–28. DOI: 10.1016/j.jacc.2016.03.524
10. Shah MR, Hasselblad V, Gheorghiade M, Adams KF, Swedberg K, Califf RM et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. The American Journal of Cardiology. 2001;88(9):987–93. DOI: 10.1016/S0002-9149(01)01975-0
11. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respiratory Medicine. 2010;104(11):1588–607. DOI: 10.1016/j.rmed.2010.08.003
12. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. European Respiratory Journal. 2004;23(1):28–33. DOI: 10.1183/09031936.03.00034603
13. Beatty AL, Schiller NB, Whooley MA. Six-Minute Walk Test as a Prognostic Tool in Stable Coronary Heart Disease: Data From the Heart and Soul Study. Archives of Internal Medicine. 2012;172(14):1096– 102. DOI: 10.1001/archinternmed.2012.2198
14. Hassan AKM, Dimitry SR, Agban GW. Can Exercise Capacity Assessed by the 6 Minute Walk Test Predict the Development of Major Adverse Cardiac Events in Patients with STEMI after Fibrinolysis? PLoS ONE. 2014;9(6):e99035. DOI: 10.1371/journal.pone.0099035
15. Schiffrin EL, Lipman ML, Mann JFE. Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation. 2007;116(1):85–97. DOI: 10.1161/CIRCULATIONAHA.106.678342
16. Савушкина О.И., Черняк А.В. Теоретические и методические аспекты бодиплетизмографии и ее клиническое применение. Бюллетень физиологии и патологии дыхания. 2016;60:117–24. DOI: 10.12737/20131
17. Budweiser S, Harlacher M, Pfeifer M, Jörres RA. Comorbidities and Hyperinflation Are Independent Risk Factors of Allcause Mortality in Very Severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2014;11(4):388–400. DOI: 10.3109/15412555.2013.836174
18. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V et al. Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2005;171(6):591–7. DOI: 10.1164/rccm.200407-867OC
19. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu C-Y, Rabinowitz D et al. Impaired Left Ventricular Filling in COPD and Emphysema: Is It the Heart or the Lungs? Chest. 2013;144(4):1143–51. DOI: 10.1378/chest.13-0183
20. Vivodtzev I, Tamisier R, Baguet J-P, Borel JC, Levy P, Pépin J-L. Arterial Stiffness in COPD. Chest. 2014;145(4):861–75. DOI: 10.1378/ chest.13-1809
21. Barr RG, Mesia-Vela S, Austin JHM, Basner RC, Keller BM, Reeves AP et al. Impaired Flow-mediated Dilation Is Associated with Low Pulmonary Function and Emphysema in Ex-smokers: The Emphysema and Cancer Action Project (EMCAP) Study. American Journal of Respiratory and Critical Care Medicine. 2007;176(12):1200–7. DOI: 10.1164/rccm.200707-980OC
22. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM et al. Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2009;180(6):513–20. DOI: 10.1164/rccm.200903-0414OC
23. Mineo D, Ambrogi V, Cufari ME, Gambardella S, Pignotti L, Pompeo E et al. Variations of Inflammatory Mediators and α1-Antitrypsin Levels after Lung Volume Reduction Surgery for Emphysema. American Journal of Respiratory and Critical Care Medicine. 2010;181(8):806– 14. DOI: 10.1164/rccm.200910-1476OC
24. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clinical and Translational Medicine. 2015;4(1):643–50. DOI: 10.1186/s40169-015-0068-z
25. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63. DOI: 10.1136/thoraxjnl-2011-201518
26. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its Resolution as Determinants of Acute Coronary Syndromes. Circulation Research. 2014;114(12):1867–79. DOI: 10.1161/CIRCRESAHA.114.302699
27. Наумов А.В., Прокофьева Т.В., Сароянц Л.В., Полунина О.С. Клиникодиагностическое значение исследования неоптерина при инфаркте миокарда на фоне хронической обструктивной болезни легких. Кубанский научный медицинский вестник. 2018;25(2):121–6. DOI: 10.25207/1608-6228-2018-25-2-121-126
28. Wouters EFM, Groenewegen KH, Dentener MA, Vernooy JHJ. Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations. Proceedings of the American Thoracic Society. 2007;4(8):626–34. DOI: 10.1513/pats.200706-071TH
29. Зафираки В.К., Космачева Е.Д. Пациент с ишемической болезнью сердца и хронической обструктивной болезнью легких в эпоху эндоваскулярных вмешательств на коронарных артериях. – М.-Краснодар: Кубанский Государственный Медицинский Университет, 2019. - 286с. ISBN 978-5-903252-12-1
30. Patel ARC, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN et al. Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2013;188(9):1091–9. DOI: 10.1164/rccm.201306-1170OC